Current Perspectives on the Systemic Management of Atopic Dermatitis

• Main Authors: Davari DR, Nieman EL, McShane DB, Morrell DS
• Format: Article
• Language: English
• Published: Dove Medical Press 2021-06-01
• Series: Journal of Asthma and Allergy
• Subjects: eczema; adults; pediatric; treatment; dupilumab
• Online Access: https://www.dovepress.com/current-perspectives-on-the-systemic-management-of-atopic-dermatitis-peer-reviewed-fulltext-article-JAA

Danielle R Davari, Elizabeth L Nieman, Diana B McShane, Dean S Morrell Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, NC, USACorrespondence: Dean S MorrellDepartment of Dermatology, University of North Carolina School of Medicine, Chapel Hill, NC, USATel [phone]Fax [phone]Email [e-mail]: Atopic dermatitis (AD) is a common disease of childhood, and some patients experience a prolonged clinical course into adolescence and adulthood. Systemic management is required when AD is not adequately controlled with topical medications. Our aim is to provide a comprehensive review of commonly used systemic immunomodulating agents in childhood and adult AD, including cyclosporine A (CsA), azathioprine (AZA), methotrexate (MTX) and mycophenolate mofetil (MMF), which are prescribed off-label in the United States, as well as dupilumab, an FDA-approved biologic. We will also provide a brief overview of emerging systemic therapies currently under investigation.Keywords: eczema, adults, pediatric, treatment, dupilumab